OSL •
Healthcare •
Biotechnology •
Quote as of 09/08/2026 16:29
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeOSL
Market Capitalization3,629.21 mln
Float218 mln
Earnings Date03/03/2027
Piotroski F-Score
2
/ 9
Weak
Relative Strength
93
/ 100
Top performer
Debt / Equity
0.02
Debt-free
ROE
-39.30
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Circio Holding ASA is a Norwegian biotechnology company, founded in 2010 and headquartered in Oslo, that focuses on developing cancer treatments based on circular RNA technology and immunotherapy. Its lead program, TG01, is a cancer vaccine designed to target specific cancer-driving mutations and is currently being tested in clinical trials for multiple myeloma, pancreatic cancer, and lung cancer. The company's circVec platform is used to engineer functional circular RNA molecules inside human cells, with ongoing partnerships supporting both its formulation and the development of a macrophage-based cell therapy approach to fighting cancer.
